Abnormal expression of serum miR‐4746‐5p in liver cancer patients after interventional chemotherapy and its possible mechanism

Abstract

AbstractInterventional chemotherapy is a common operation in the clinical treatment of liver cancer. The aim of this study was to investigate the expression and molecular mechanism of serum miR‐4746‐5p in liver cancer patients before and after interventional chemotherapy. The levels of miR‐4746‐5p and CDKN1C in serum samples from liver cancer patients were detected using real‐time fluorescence quantitative polymerase chain reaction. Receiver operating characteristic curves revealed the diagnostic value of miR‐4746‐5p in tumors. Differences in clinical indicators between liver cancer patients and healthy controls were assessed using Pearson correlation analysis. Luciferase reporter gene assays confirmed the targeted interaction between miR‐4746‐5p and CDKN1C. In vitro cellular assays were validated by Cell Counting Kit‐8, Transwell assay, and chemoresistance assay. Serum miR‐4746‐5p levels were increased in liver cancer patients but were downregulated after chemotherapy intervention. CDKN1C expression showed the opposite trend. Low levels of miR‐4746‐5p mediated cell growth and metastasis by targeting and negatively regulating CDKN1C expression, while silencing CDKN1C restored cell activity. Inhibition of miR‐4746‐5p reduced chemoresistance, while downregulation of CDKN1C affected cell sensitivity. miR‐4746‐5p may be a potential therapeutic factor for liver cancer diagnosis and interventional chemotherapy.